Bolt Biotherapeutics Announces Issuance of U.S. Patent for the Boltbody™ ISAC Technology and its Lead Development Candidate, BDC-1001
About Andrea Tu
This author has yet to write their bio.
Meanwhile lets just say that we are proud Andrea Tu contributed a whooping 52 entries.
Phase 1/2 study of novel HER2-targeting, TLR7/8 immune-stimulating antibody conjugate (ISAC) BDC-1001 as a single agent and in combination with an immune checkpoint inhibitor in patients with advanced HER2-expressing solid tumors Presented at: 2020 San Antonio Breast Cancer Symposium
Bolt Biotherapeutics Appoints William P. Quinn as Chief Financial Officer
Bolt Biotherapeutics Appoints Edith Perez, M.D., as Chief Medical Officer
Bolt invited to present: 2020 Jefferies Virtual Healthcare Conference June 3, 2020
Bolt Biotherapeutics Appoints Nathan Ihle, Ph.D., as Vice President of CMC and Quality
Bolt Biotherapeutics Initiates Immunotherapy Trial of Lead Drug Candidate in HER2-Expressing Solid Tumors Precision Oncology News
Bolt Biotherapeutics Announces Initiation of BDC-1001 Clinical Trial in Patients with HER2-Expressed Solid Tumors
Bolt Bio Preps Clinical Trials of Immune-Stimulating Cancer Drug in Stubborn Solid Tumors FierceBiotech
You acknowledge that the personal information you provide to Bolt Biotherapeutics will be processed to respond to your request or inquiry. For more information, please review our Privacy Notice .